# Menarini Group Menarini Group is a Corporate Investor based in Florence, Italy. ## Overview - **Organization type:** Corporate Investor - **Headquarters:** Florence, Italy - **Region:** Europe - **Address:** Via Sette Santi, 50131 Florence, Italy - **Founded:** 1886 - **Assets under management:** Undisclosed - **Website:** www.menarini.it - **LinkedIn:** https://it.linkedin.com/company/menarini ## Regulatory record - **Reports private funds:** No ## About Menarini Group was founded in Naples in 1886 as a small pharmacy and moved its headquarters to Florence over a century ago. The Aleotti family gained control in the mid-20th century, and today the group operates as a privately held pharmaceutical corporation with commercial reach across 140 countries. The 2023 death of chairman Alberto Aleotti left his widow, Massimiliana Landini Aleotti, as the primary shareholder, with daughter Lucia and son Alberto Giovanni serving as board members and stewards of the family's industrial legacy. The firm's venture posture centers on direct corporate partnerships and selective equity investments that complement its internal research pipeline. Menarini targets oncology, cardiovascular disease, and inflammatory conditions, and has moved deliberately into AI-enabled drug discovery—most visibly through a strategic collaboration with Insilico Medicine to develop novel cancer drug candidates. The group also in-licenses clinical-stage assets, as seen in its European licensing deal for obicetrapib, a cardiovascular candidate from NewAmsterdam Pharma. Commercial hubs in Berlin, Barcelona, Singapore, and La Jolla support a registered portfolio of more than 100 products, while Berlin-Chemie AG, a wholly owned Menarini subsidiary, anchors its German market presence. The family's investment governance ties venture decisions directly to the corporate parent rather than to a separate family office or venture arm. Lucia Aleotti, a former president of Menarini and a council member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), helps steer capital allocation alongside her brother Alberto Giovanni, the former vice chairman. The Aleottis maintain non-pharma assets as well—Menarini Art Monographs and the Pills of Art digital program reflect a long-standing patronage of Renaissance art scholarship—but the group's external investment activity remains concentrated on biotech. Menarini's structural distinction lies in its permanence: a 138-year-old family-held operating company that funds venture-stage science without a fund structure, a limited-partner base, or a defined deployment cycle. The absence of external investor pressure allows the Aleotti family to hold positions indefinitely, blending the patience of a single-family office with the scale and distribution network of a global pharma company. ## Sectors - Pharmaceuticals - Consumer Healthcare - AI/ML - Digital Health ## Offices - Berlin, Germany - Badalona (Barcelona), Spain - Singapore - La Jolla, CA, USA ## People - Massimiliana Landini Aleotti — Primary Shareholder - Lucia Aleotti — Shareholder, Board Member - Alberto Giovanni Aleotti — Shareholder, Board Member ## Questions ### How does Menarini source its biotech investments? Menarini sources investments almost entirely through scientific collaborations and in-licensing partnerships that align with its internal R&D priorities—oncology, cardiovascular, and inflammatory diseases. The group looks for clinical-stage assets and enabling technologies, such as the AI drug-discovery platform it co-develops with Insilico Medicine, that it can integrate into its existing development and commercial infrastructure. ### Does Menarini Group maintain any non-pharmaceutical structures or vehicles? Yes. The Fondazione Internazionale Menarini serves as the family's dedicated philanthropic vehicle, funding scientific symposia and medical education programs. The group also runs Menarini Art Monographs and the Pills of Art digital initiative, which support art-historical research and public scholarship on the Italian Renaissance—a cultural interest pursued alongside, but fully separated from, the pharmaceutical business. ### What investment stages does Menarini Group typically target in biotech? Menarini favors clinical-stage assets and platform technologies that have moved beyond early scientific proof-of-concept. Its collaboration with Insilico Medicine targets pre-clinical candidates generated by AI, while the obicetrapib licensing agreement with NewAmsterdam Pharma brought a Phase 3-ready asset into Menarini's European portfolio—demonstrating a preference for later-stage therapeutics with clear regulatory paths. ## Related profiles - [Menara Ventures](https://altss.com/profile/menara-ventures) - [MENA Technology Fund](https://altss.com/profile/mena-technology-fund) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/menarini-group Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology